BMO Capital Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $15
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Kostas Biliouris maintains an 'Outperform' rating on Centessa Pharmaceuticals (NASDAQ:CNTA) and raises the price target from $11 to $15.
July 25, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital maintains an 'Outperform' rating on Centessa Pharmaceuticals and raises the price target from $11 to $15.
The raised price target by BMO Capital indicates a positive outlook for Centessa Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100